Chen X, Zheng C J, Han L Y, Xie B, Chen Y Z
Bioinformatics and Drug Design Group, Department of Pharmacy, National University of Singapore, Singapore 117543.
Endocr Metab Immune Disord Drug Targets. 2007 Sep;7(3):225-31. doi: 10.2174/187153007781662576.
A number of therapeutic targets have been explored for developing drugs in the treatment of endocrine, metabolic and immune disorders. Continuous efforts and increasing interest have been directed at the search of new targets. Data from the therapeutic target database at http://bidd.nus.edu.sg/group/cjttd/ttd.asp, shows that there are 26, 24, and 22 targets of marketed drugs for the treatment of these three classes of diseases, respectively. The number of targets of investigational agents has reached 98, 124, and 72, respectively. An analysis of these targets, particularly those of recently approved drugs and patented investigational agents, provides useful hint about the general trends of target exploration, with current focus on drug discovery and the difficulties encountered in developing drugs against these targets. Multiple profiles of these targets have been analyzed to probe the sequence, structural, physicochemical and systems-related features contributing to the successful exploration of a target against these diseases.
为开发用于治疗内分泌、代谢和免疫紊乱的药物,人们探索了许多治疗靶点。针对寻找新靶点,人们持续付出努力并表现出越来越浓厚的兴趣。来自http://bidd.nus.edu.sg/group/cjttd/ttd.asp治疗靶点数据库的数据显示,用于治疗这三类疾病的上市药物的靶点分别有26个、24个和22个。研究药物的靶点数量分别已达98个、124个和72个。对这些靶点进行分析,尤其是对最近获批药物和已获专利的研究药物的靶点进行分析,能为靶点探索的总体趋势提供有用线索,包括当前药物研发的重点以及针对这些靶点开发药物时遇到的困难。已对这些靶点的多种特征进行分析,以探究有助于成功探索针对这些疾病的靶点的序列、结构、物理化学和系统相关特征。